MAPT and Alzheimer disease: In the present study, we expanded these findings by demonstrating that plasma NTA-tau is increased across the AD continuum, starting to emerge subtly already at preclinical AD stages in asymptomatic cases, and showing that the bulk of the increase occurs between MCI+ and AD+ , with the latter group showing the highest concentrations among all investigated clinical groups.